Ignite Creation Date:
2024-05-05 @ 10:43 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01178151
Status:
WITHDRAWN
Last Update Posted:
2015-04-22
First Post:
2010-07-26
Brief Title:
Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome
Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Organization:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Study Overview
Official Title:
Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome
Status:
WITHDRAWN
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EVAMP
Brief Summary:
In this pilot study the investigators will treat all patients known with Peutz-Jeghers syndrome PJS who are diagnosed with advanced malignancies with everolimus 10mg daily until disease progression Most patients with PJS have an inherited LKB1 mutation leading to aberrant m-TOR activity Their risk to develop malignancies or intestinal polyps is probably related to this constitutive mTOR signaling The hypothesis is that mTOR inhibition is an effective anticancer treatment in PJS patients with advanced malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-020451-32 | EUDRACT_NUMBER | None | None |